Q2 2023 · 13F-HR
CAXTON CORPholdings as filed
Filed 2023-08-14 · accession 0000919574-23-004721
$34.7M
Reported value
7
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 805111101 | SVRA | SAVARA INC | $16.0M | 46.2% | 4,980,804 | Common | SOLE |
| 98422E103 | XERS | XERIS BIOPHARMA HOLDINGS INC | $14.8M | 42.7% | 5,641,920 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $2.6M | 7.54% | 1,318,967 | Common | SOLE |
| 608550109 | — | MOLECULAR TEMPLATES INC | $985,436 | 2.84% | 2,052,991 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $138,220 | 0.40% | 43,466 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $77,318 | 0.22% | 17,733 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $33,022 | 0.10% | 21,725 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.